Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17848601 | 0.98 | KDM4E (0.44) | KDM4EKMT2AFFAR3CYP1A2CCR2 | |
| SCHEMBL29640099 | 0.87 | KDM4E (0.38) | KDM4EKMT2AFFAR3CYP3A4SMN1; SMN2 | |
| SCHEMBL8567866 | 0.83 | — | — | |
| SCHEMBL31057956 | 0.82 | KDM4E (0.41) | KDM4EKMT2AFFAR3CYP1A2CCR2 | |
| SCHEMBL13747397 | 0.78 | KDM4E (0.38) | KDM4EKMT2AFFAR3CYP1A2CCR2 | |
| SCHEMBL23199626 | 0.78 | CETP (0.42) | FFAR3CCR2DRD2CYP3A4SMN1; SMN2 | |
| SCHEMBL10224418 | 0.78 | — | — | |
| SCHEMBL24025620 | 0.77 | KMT2A (0.38) | KDM4EKMT2ACYP1A2CCR2KHK | |
| SCHEMBL25229077 | 0.77 | ALDH1A1 (0.40) | KDM4EKMT2AFFAR3CYP1A2CCR2 | |
| SCHEMBL25221272 | 0.77 | CYP1A2 (0.49) | KDM4EKMT2AFFAR3CYP1A2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062818-A | Novel SOS1 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2022184116-A1 | NEW SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏先声药业有限公司 | 2022-09-09 | — | — | WO | disclosed |
| WO-2022161461-A1 | SOS1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127328-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2017096045-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-3091012-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Centrexion Therapeutics Corporation (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | KDM4E 3994/4885KMT2A 2199/4885FFAR3 156/4885 |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | KDM4E 4433/4885KMT2A 2955/4885FFAR3 374/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | KDM4E 4325/4885KMT2A 2861/4885FFAR3 305/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | KDM4E 4204/4885KMT2A 2003/4885FFAR3 308/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | KDM4E 4650/4885KMT2A 4077/4885FFAR3 241/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | KDM4E 2203/4885KMT2A 2461/4885FFAR3 394/4885 |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR5, CCR1 | KDM4E 3028/4885KMT2A 1768/4885FFAR3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.